Contact Home Home
Back to Events List

Prof. Oded Shoseyov
Business Lunch

WHEN:
Friday 6 October
WHERE:
InterContinental Adelaide
TICKETS:
AICC Members : $165
Non Members : $180
Book This Event
Open State

We are pleased to invite you, your guests and collegues to

A Business Luncheon with

'The benefits of Nano Biotechnology'

Prof. Oded Shoseyov, The Hebrew University of Jerusalem, Founder of Collplant and Co-Founder of SP Nano Ltd

Prof. Oded Shoseyov is a Co-Founder of SP Nano Ltd. and serves as its Scientific Advisor. He is also the Scientific Founder of CBD Technologies, FuturaGene, Melodea and Bondex. He founded Collplant Holdings Ltd. in 2004 and has been its Chief Scientist Officer since August 2008. He serves as Chief Scientist at CBD Technologies Ltd. Prof. Shoseyov is a Founder of Fulcrum SP Ltd and Faculty Member of the Institute of Plant Science and Genetics in Agriculture and the Otto Warburg Center for Agricultural Biotechnology at the Faculty of Agriculture, Food and Environmental Quality Sciences of the Hebrew University of Jerusalem.

Oded’s main field of research is plant molecular biology and biotechnology. He has extensive experience with genetic engineering of plants, protein engineering and nano-biotechnology. He serves as a Member of Advisory Board at EQUI-nom Ltd. Oded serves as a Member of Scientific Advisory Board of FuturaGene Plc (now known as FuturaGene, LTD.). He served as a Director of Collplant Holdings Ltd. from May 20, 2010 to October 2016. 

Oded is the Inventor and Co-inventor of more than 14 patents, 9 of which relate directly to CBD Technologies business. He has authored or co-authored more than 160 scientific publications and is the inventor or co-inventor of 42 patents. He has received numerous awards and appointments for his research in agricultural biotechnology. Prof. Shoseyov received the Outstanding Scientist Polak Award for 2002 and the 1999 Kay Award for Innovative and Applied Research. He received his B.S. with Excellence in 1981, his M.S. with Excellence in 1983 and his Ph.D. summa cum laude in 1988 from the Hebrew University of Jerusalem.

One of the companies he founded, Collplant, is an agro-biotech regenerative medicine company focused on developing and commercialising products for the orthobiologics and wound care markets. Collplant’s technology allows the cost efficient production of high quality recombinant type 1 human collagen (rhCollagen) using tobacco plants carrying ve human genes. The addressable market size is multiple USD billions, with collagen selling for USD1 million per kilogram.

Professor Shoseyov is encouraged by the Hebrew University of Jerusalem to commercialise his research. As a result they have retained the serial entrepreneur and leading scientist who in turn attracts more students and research partners to the university. This industry-driven, solution-oriented approach contrasts with the application driven science that is more commonplace in Australia. In fact, Australia ranks as the country with the lowest level of higher education or public research- industry innovation collaboration in the OECD.

 

Book This Event

Event partners

Open State